insights_auto
Why is ALKS down 2,69%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
44,94 $
arrow_downward
-2,69%(-1,24) 1D
45,50 $
arrow_upward
+1,25% (+0,56)bedtimeAfter hours
Closed: 20 қар., 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
45,79 $
High
46,89 $
Low
44,83 $
Mkt. cap
7,55 млрд
Avg. vol.
1,71 млн
Volume
1,08 млн
52-wk high
55,67 $
52-wk low
27,00 $
EPS
-0,01 $
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 мың
Open
45,79 $
High
46,89 $
Low
44,83 $
Mkt. cap
7,55 млрд
Avg. vol.
1,71 млн
Volume
1,08 млн
52-wk high
55,67 $
52-wk low
27,00 $
EPS
-0,01 $
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 мың
News stories
From web sources and news partners
GuruFocus
·
2 күн бұрын
A Look at Alkermes PLC (ALKS) After 3.1% Gain -- GF Value $33.66 vs Price $46.85
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 мың
Founded1987
Headquarters-
SectorHealth Care
Industry-
Websitealkermes.com